Skip to main content

Coronavirus disease 19 and risk of hyperglycemia among Iraqi patients

Abstract

A cross-sectional observational study was conducted on 213 patients with COVID-19 who did not have a clinical history of diabetes at hospital admission. One week after hospitalization, they were stratified by random blood glucose levels. It was found that 25.4, 22.5 and 52.1% of COVID-19 patients were classified as normoglycemia, prediabetes and diabetes, respectively. The study indicated that diabetes may be a risk factor for COVID-19 or the disease may be associated with an increased risk of developing diabetes.

The World Health Organization (WHO) and health authorities have devoted significant attention to understanding risk factors for coronavirus disease 19 (COVID-19) and their role in disease outcomes [1]. Several predictors were identified by a comparative analysis of risk factors across 17 studies, and age and diabetes were considered to be highly consistent [2]. Additional data support the concept that diabetes and other related diseases (hypertension and cardiovascular diseases) are the most common comorbidities in COVID-19 patients [3, 4]. It has also been proposed that COVID-19 is likely associated with an increased risk of developing diabetes [5]. This motivated us to conduct a study to explore the incidence of diabetes in hospitalized COVID-19 cases.

A multicenter cross-sectional observational study was conducted on 213 patients diagnosed with COVID-19 at referral hospitals for the management of COVID-19 in Baghdad during the period from 1 October to 15 November 2020. COVID-19 was molecularly diagnosed by detection of virus RNA in patients' nasopharyngeal secretions (reverse transcription–polymerase chain reaction test). The included patients were those who did not have a clinical history of diabetes when they were admitted to hospitals. One week after hospitalization, the records of these patients were inspected for age, gender, body mass index (BMI), ABO and Rh blood groups, hemoglobin (Hb), platelet count, white blood cell count (WBC), erythrocyte sedimentation rate (ESR), random blood glucose (RBG), and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total cholesterol, triglycerides, creatinine and blood urea nitrogen.

Continuous variables were given as mean and standard deviation (SD), and one-way analysis of variance (ANOVA) followed by Duncan's multiple-range post hoc test was used to assess significant differences. Categorical variables were expressed by number and percentage, and Pearson Chi-squared test was used to assess significant differences. A probability value (p) ≤ 0.05 was considered significant. The IBM SPSS Statistics 25.0 (Armonk, NY: IBM Corp.) was used to perform these analyses.

The mean age of COVID-19 patients was 57.4 ± 15.3 years. Males outnumbered females (86.4 vs. 13.6%). Most patients were overweight/obese (79.8%). Blood group O was the most common (37.6%), followed by blood groups A, B and AB (31.5, 21.6 and 9.4%, respectively). Rh-negative phenotype was present in 16.9% of patients. Other laboratory data were either within the normal range (Hb, platelets, ALT, AST and ALP) or above (WBC, ESR, and RBG). The RBG was higher than the normal range (269.5 ± 179.4 vs. 79 to < 140 mg/dL). Thus, hyperglycemia might have been identified in COVID-19 patients. This finding prompted us to re-examine the RBG and categorize patients into normoglycemia (79 to  < 140 mg/dL), prediabetes (140–199 mg/dL) and diabetes (≥ 200 mg/dL) according to the American Diabetes Association criteria [6]. It was found that 25.4% of COVID-19 patients were classified as normoglycemia, 22.5% as prediabetes and 52.1% as diabetes. It was also noted that the mean age paralleled the categorization gradually; 53.2 ± 16.8 years for normoglycemia, 55.6 ± 15.7 years for prediabetes and 60.4 ± 13.7 years for diabetes, and the difference was significant (p value = 0.01). As for gender, BMI and blood groups, their distribution in the three groups of patients did not show significant differences. The blood parameters also showed no significant differences between normoglycemia, prediabetes and diabetes. Platelets, RBG and ALP were exceptions and showed significant differences between the three groups of patients (Table 1 and Fig. 1).

Table 1 Characteristics of COVID-19 patients
Fig. 1
figure 1

Scatter dot plot of random blood glucose in COVID-19 patients with normoglycemia (109.1 ± 23.7 mg/dL), prediabetes (167.6 ± 19.0 mg/dL) or diabetes (391.6 ± 170.6 mg/dL). Mean and standard deviations are indicated by horizontal and vertical lines respectively

The main interest of this study was to observe if COVID-19 in general is linked to an altered RBG or diabetic condition. The results indicated that this infection was associated with an increased incidence of diabetes or diabetes may be a risk factor for the development of COVID-19. Some COVID-19 patients might have developed hyperglycemia after hospitalization, while their clinical history did not indicate any evidence of diabetes; 22.5% prediabetes and 52.1% diabetes. Thus, the role of COVID-19 in the development of diabetes was proposed. Consistent with our observation, it has been reported that hyperglycemia occurred in 33.2% of COVID-19 patients during hospitalization, and the proportion was higher in severe cases compared to nonsevere cases (45.4 vs. 21.5%) [5]. Accordingly, it has been hypothesized that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce insulin secretion through its effects on pancreatic β-cell function [7, 8]. The SARS-CoV-2 receptor (ACE2: angiotensin-converting enzyme 2) has been shown to be expressed by pancreatic cells, as well as other metabolic organs and tissues (for instance, adipose tissue, intestine and kidneys). Therefore, the virus may cause multidirectional changes in glucose metabolism that could complicate pre-existing diabetes or lead to the development of hyperglycemia in non-diabetic patients [9]. Furthermore, it has also been demonstrated that COVID-19 patients are markedly characterized by elevated serum levels of pro-inflammatory cytokines; for instance, interleukin (IL)-1, IL-6, IL-12, interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) [10, 11]. Inflammation due to high production of cytokines may lead to insulin resistance and may impair insulin production by pancreatic β-cell [8].

Equally important, most current COVID-19 patients were overweight/obese (79.8%), and there has been strong evidence to suggest that obesity is involved in the pathogenesis of diabetes [12]. More importantly, a global estimate revealed that 45.8% of all adult diabetes cases were undiagnosed, and almost a similar proportion was reported in Iraq (47.05%) [13]. Therefore, although the patients of this study did not have a clinical history of diabetes, they may represent undiagnosed cases especially if we consider their overweight/obese status. Taken together, these data suggest that diabetes may be considered a risk factor for COVID-19, or the infection may put non-diabetic patients at risk for developing diabetes. However, additional prospective studies are warranted to understand the pathophysiology of COVID-19 in diabetic and non-diabetic patients, and to limit confounding biases due to observational design [14].

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

ACE2:

Angiotensin-converting enzyme 2

BMI:

Body mass index

COVID-19:

Coronavirus disease 19

IFN-γ:

Interferon-gamma

IL:

Interleukin-1 (IL-1)

RBG:

Random blood glucose

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2

TNF-α:

Tumor necrosis factor-alpha

References

  1. Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A et al (2020) World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71–76. https://doi.org/10.1016/j.ijsu.2020.02.034

    Article  PubMed  PubMed Central  Google Scholar 

  2. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J (2020) A brief-review of the risk factors for covid-19 severity. Rev Saude Publica 54:60. https://doi.org/10.11606/S1518-8787.2020054002481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zhang P, Wang M, Wang Y, Wang Y, Li T, Zeng J et al (2021) Risk factors associated with the progression of COVID-19 in elderly diabetes patients. Diabetes Res Clin Pract 171:108550. https://doi.org/10.1016/j.diabres.2020.108550

    Article  CAS  PubMed  Google Scholar 

  4. Tadic M, Cuspidi C, Sala C (2020) COVID-19 and diabetes: is there enough evidence? J Clin Hypertens 22:943–948. https://doi.org/10.1111/jch.13912

    Article  CAS  Google Scholar 

  5. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146:110–118. https://doi.org/10.1016/j.jaci.2020.04.006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Association AD (2019) Classification and diagnosis of diabetes: standards of medical care in diabetesd2019. Diabetes Care 42:S13-28. https://doi.org/10.2337/dc19-S002

    Article  Google Scholar 

  7. Ceriello A (2020) Hyperglycemia and COVID-19: What was known and what is really new? Diabetes Res Clin Pract 167:108383. https://doi.org/10.1016/j.diabres.2020.108383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ceriello A, De Nigris V, Prattichizzo F (2020) Why is hyperglycaemia worsening COVID-19 and its prognosis? Diabetes Obes Metab 22:1951–1952. https://doi.org/10.1111/dom.14098

    Article  CAS  PubMed  Google Scholar 

  9. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH et al (2020) New-onset diabetes in Covid-19. N Engl J Med 383:789–790. https://doi.org/10.1056/nejmc2018688

    Article  PubMed  Google Scholar 

  10. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Raony Í, Saggioro de Figueiredo C (2020) Retinal outcomes of COVID-19: Possible role of CD147 and cytokine storm in infected patients with diabetes mellitus. J Clean Prod 165:108280. https://doi.org/10.1016/j.diabres.2020.108280

    Article  CAS  Google Scholar 

  12. Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P (2018) Obesity and diabetes—not only a simple link between two epidemics. Diabetes Metab Res Rev 34:e3042. https://doi.org/10.1002/dmrr.3042

    Article  PubMed  PubMed Central  Google Scholar 

  13. Beagley J, Guariguata L, Weil C, Motala AA (2014) Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 103:150–160. https://doi.org/10.1016/j.diabres.2013.11.001

    Article  PubMed  Google Scholar 

  14. Cariou B, Pichelin M, Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C et al (2021) Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study. Diabetes Res Clin Pract 175:108695. https://doi.org/10.1016/j.diabres.2021.108695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors appreciate the kind help and cooperation of the medical staff in hospitals of Al-Karkh District in Baghdad.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

The three authors (AHA, NTA and AAA) contributed equally to data management, statistical analyzes, and manuscript writing and reviewing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ali H. Ad’hiah.

Ethics declarations

Ethics approval and consent to participate

The Ethics Committee at the Iraqi Ministry of Health and Environment approved the study (Approval number: 68130 on 10/11/2020).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ad’hiah, A.H., Al-Bayatee, N.T. & Ahmed, A.A. Coronavirus disease 19 and risk of hyperglycemia among Iraqi patients. Egypt J Med Hum Genet 22, 82 (2021). https://doi.org/10.1186/s43042-021-00207-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43042-021-00207-3

Keywords

  • COVID-19
  • Diabetes
  • Hyperglycemia
  • Prediabetes
  • Random blood glucose